Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- Japan

Publisher Name :
Date: 31-Jan-2017
No. of pages: 40
Price : Single User: US $ 1750  US $ 1488 Corporate User: US $ 5250  US $ 3675
This report is available at 15% Discount for Single User License and 30% Discount for Corporate Users License till 30 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-Japan" report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes global market size of the Graft Versus Host Disease (GVHD) for Japan.

GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight's estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.73% from 2013-2023 and reach up to 7,025 cases in the year 2023.

The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 2.88 % and 1.57%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 2.88% and 1.57%, respectively, by the end of the year 2023.

The market size of GVHD mainly comprises of the off-label biologics. Many companies are working on the development of targeted therapy and in the near future, these drugs may create an impact on the overall market size of GVHD. DelveInsight's estimates suggest that the forecasted market size of Graft Versus Host Disease (GVHD) in Japan shall increase at a CAGR of 4.80% from 2013 to 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

- It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) ( which also includes the cases of first transplants along with the total transplants)

- The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for Japan from 2013-2023.

- The Report also includes historical and forecasted Market size of GVHD for Japan from 2013 to 2023.

- It provides the information of available marketed therapies, including off-label biologics, patent and exclusivity details.

- The report also focuses on the details of pipeline drugs in the pivotal stage of development including their SWOT Analysis and expected launch date, which shall help to predict the impact of those drugs on the market size in the near future.

?

This report is available at 15% Discount for Single User License and 30% Discount for Corporate Users License till 30 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- Japan

Table of Contents

Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GVHD
Chronic GVHD
Grades of GVHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
Assumptions and Rationale
Treatment Algorithm
Guidelines and Recommendations for Treatment of GVHD in Japan
Current Unmet Needs of Graft Versus Host Disease (GVHD)
Marketed Drugs
Temcell HS
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Temcell HS
Side effects of Temcell HS
SWOT Analysis of Temcell HS
Remicade
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Remicade
Side effects of Remicade
SWOT Analysis
Lemtrada
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Lemtrada
Adverse reactions of Lemtrada
SWOT Analysis
Velcade
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Velcade
Side effects of Velcade
SWOT Analysis
Gleevec
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Gleevec
Adverse reactions of Gleevec
SWOT Analysis
Rapamune
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Rapamune
Adverse reactions of Rapamune
SWOT Analysis
Simulect
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Simulect
Side effects of Simulect
SWOT Analysis
Enbrel
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Enbrel
Side effects of Enbrel
SWOT Analysis
Orencia
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Orencia
Side effects of Orencia
SWOT Analysis
Nulojix
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Nulojix
Side effects of Orencia
SWOT Analysis
Emerging Drugs Analysis
Emerging Drugs
Begelomab
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Budesonide
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Methoxsalen
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Market Size
Japan
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight


List of Tables

Table 1: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Table 2: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 3: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 4: GVHD Prophylaxis regimen for Myeloablative conditioning
Table 5: GVHD Prophylaxis regimen for Reduced intensity conditioning
Table 6: Begelomab, Clinical Trials by Zone, 2017
Table 7: Clinical Trials by Recruitment status, 2017
Table 8: Budesonide, Clinical Trials by Zone, 2017
Table 9: Clinical Trials by Recruitment status, 2017
Table 10: Methoxsalen, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Recruitment status, 2017
Table 12: Japan market size of GVHD in USD, Million (2013-2023)
Table 13: Japan market size of GVHD by treatment type in USD, Million (2013-2023)


List of Figures

Figure 1: Pathophysiology of GVHD
Figure 2: Risk Factors for GVHD
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Figure 4: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Figure 5: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Figure 6: Treatment Algorithm of GVHD
Figure 7: Begelomab, Clinical Trials by Zone (%), 2017
Figure 8: Begelomab, Clinical Trials by Recruitment status (%), 2017
Figure 9: Budesonide, Clinical Trials by Zone (%), 2017
Figure 10: Budesonide, Clinical Trials by Recruitment status (%), 2017
Figure 11: Methoxsalen, Clinical Trials by Zone (%), 2017
Figure 12: Methoxsalen, Clinical Trials by Recruitment status (%), 2017
Figure 13: Spain market size of GVHD in USD, Million (2013-2023)
Figure 14: Japan market size of GVHD in USD, Million (2013-2023)
Figure 15: Japan market size of GVHD by treatment type in USD, Million (2013-2023)
  • Asia-Pacific Procalcitonin (CAS 56645-65-9) Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 116
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. Scope of the Report: This report focuses on the Procalcitonin (CAS 56645-65-9) in Asia-Pacific mar......
  • Europe Hyoscine-N-Butyl Bromide Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 118
    Hyoscine-N-Butyl Bromideis obtained from a species of the plant genus Duboisia. It is mainly classified as an antispasmodic, which means that it is a drug used to suppress of muscle spasms, or involuntary contractions. Scope of the Report: This report focuses on the Hyoscine-N-Butyl Bromide in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes the market based on manufacturers, countries, type and application. Market ......
  • Europe Medical Grade Hydrogel Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 117
    Hydrogel is gel-like or colloidal substances made of water and solids. Hydrogels are highly absorbent (they can contain over 90% water) natural or synthetic polymeric networks. It is widely used in medical fields, industrial fields, consumer goods etc. Scope of the Report: This report focuses on the Medical Grade Hydrogel in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes the market based on manufacturers, countries, type and app......
  • Global Pneumonia Vaccine Market Research Report 2017
    Published: 27-Jun-2017        Price: US 2900 Onwards        Pages: 109
    In this report, the global Pneumonia Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pneumonia Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China -......
  • Asia-Pacific Organ Transplant Immunosuppressant Drugs Market Report 2017
    Published: 26-Jun-2017        Price: US 4000 Onwards        Pages: 126
    In this report, the Asia-Pacific Organ Transplant Immunosuppressant Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Organ Transplant Immunosuppressant Drugs for these regions, from 2012 to 2022 (forecast), including - Chi......
  • EMEA (Europe, Middle East and Africa) Anthrax Vaccines Market Report 2017
    Published: 26-Jun-2017        Price: US 4000 Onwards        Pages: 125
    In this report, the EMEA Anthrax Vaccines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Anthrax Vaccines for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; ......
  • Asia-Pacific Povidone Iodine (PVP-I) Market Report 2017
    Published: 26-Jun-2017        Price: US 4000 Onwards        Pages: 116
    In this report, the Asia-Pacific Povidone Iodine (PVP-I) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Povidone Iodine (PVP-I) for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Ko......
  • Asia-Pacific Budesonide Sprays Market Report 2017
    Published: 26-Jun-2017        Price: US 4000 Onwards        Pages: 119
    In this report, the Asia-Pacific Budesonide Sprays market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Budesonide Sprays for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Korea ......
  • United States Calcitriol (CAS 32222-06-3) Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 26-Jun-2017        Price: US 4480 Onwards        Pages: 116
    Calcitriol is a white, crystalline compound which occurs naturally in humans. It has a calculated molecular weight of 416.65 and is soluble in organic solvents but relatively insoluble in water. Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. The report focus on the Calcitriol formulations market survey. Scope of the Report: This report focuses ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs